IPR Estoppel Does Not Bar Commission Investigative Staff from Asserting Prior Art References in an ITC Investigation

Oct 15, 2018

Reading Time : 1 min

The estoppel provision of 35 U.S.C. § 315(e)(2) prohibits the “petitioner . . .[,] real party in interest or privy of the petitioner” from raising grounds of invalidity that were “raised or reasonably could have [been] raised, during [IPR]” in a district court litigation or an investigation before the ITC.   

Prior to the instant ITC investigation, respondent Fujifilm had petitioned for IPR of one of Sony’s patents. The PTAB instituted review of the patent, but determined (in its final written decision) that it was not unpatentable. In the ITC investigation, Sony asserted the same patent against Fujifilm and contended that Fujifilm was estopped from relying on prior art references asserted in the IPR.

Sony also went one step further by arguing that the Commission Investigative Staff were estopped from asserting Fujifilm’s IPR references. In response, the Staff argued that 35 U.S.C. § 315(e)(2) “only estops the petitioner in an inter partes review,” and further that it was not a petitioner or even a party to the IPR. The ALJ found the Staff’s argument persuasive and held that “Regardless of whether 35 U.S.C. § 315(e)(2) estops Fujifilm, as contended by Sony, the statute does not prevent Staff from raising the references in this investigation, which it did.”  With the estoppel issue resolved, ALJ Cheney addressed the prior art references and found the asserted claims of the Sony patent invalid for anticipation and obviousness.  

Practice Tip:  Patent owners should be cognizant that, in ITC investigations, the estoppel provision of 35 U.S.C. § 315(e)(2) has been interpreted as being strictly limited to the petitioner, the real parties-in-interest or privies of the petitioner—but not encompassing the Commission Investigative Staff. This leaves open the possibility of the Staff raising invalidity challenges that have been previously rejected by the PTAB.

In the Matter of Certain Magnetic Tape Cartridges and Components Thereof, 337-TA-1058 (ITC October 2, 2018, Order) (Cheney, ALJ).

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.